NEURODON, LLC
Saint John, IN · Founded 2019 · CIK 0001793427 · Biotech · Private
Small molecule positive allosteric modulators (PAMs) of SERCA protein for neuroprotection in Alzheimer's disease
neurodon.net →- Grants
- $5.9M
- 8 awards
- Sector median: 1
- Raised
- $500K
- 1 Form D · Nov 2019
- 83 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer’s disease | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease | $225,000 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease | $988,940 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease | $1,989,595 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease | $1,000,655 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical evaluation of SERCA2 allosteric activators for pancreatic β-cell protection in diabetes. | $286,348 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease | $529,129 | |
| Federal grant | Department of Health and Human Services · Phase II · Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease | $694,864 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2598 | Mitochondria in Motion, Inc. | — | — |
| 2599 | SKYRAN BIOLOGICS, INC. | — | — |
| 2600 | Aurora Bio, Inc. | — | — |
| 2601 | NEURODON, LLC | — | $500K |
| 2602 | JumpStart Fertility, Inc. | — | $500K |
| 2603 | ENFUEGO THERAPEUTICS, INC. | — | $500K |
| 2604 | CHAPERONE THERAPEUTICS, INC. | — | $457K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Russell DahlDirector · Executive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.